Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
17.21
+0.26 (1.53%)
Dec 3, 2024, 2:09 PM EST - Market open
Centessa Pharmaceuticals Revenue
Centessa Pharmaceuticals had revenue of $6.85M in the twelve months ending September 30, 2024. In the year 2023, Centessa Pharmaceuticals had annual revenue of $6.85M.
Revenue (ttm)
$6.85M
Revenue Growth
n/a
P/S Ratio
261.97
Revenue / Employee
$90,171
Employees
76
Market Cap
2.27B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.85M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Addus HomeCare | 1.13B |
Omnicell | 1.06B |
Amphastar Pharmaceuticals | 723.55M |
NeoGenomics | 644.12M |
Beam Therapeutics | 349.64M |
Mirum Pharmaceuticals | 307.03M |
Ligand Pharmaceuticals | 152.42M |
Wave Life Sciences | 53.61M |
CNTA News
- 21 days ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares - GlobeNewsWire
- 2 months ago - Nxera Pharma's Partner Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers - GlobeNewsWire
- 3 months ago - Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) - GlobeNewsWire
- 3 months ago - Centessa Pharmaceuticals to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewsWire